Artal Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Artal Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-50,000	Closed	-$5.59M	–	123
2019 Q1	$5.59M	Buy	+50,000	New	+$5.46M	0.23%	71

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Artal Group's ICPT Position: Q2 2019 in Review

Artal Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2019, closing a stake of 50,000 shares — an estimated $5.59M sold.

Artal Group first reported a position in ICPT in Q1 2019 and held it in 1 quarter. The position peaked at $5.59M in Q1 2019. 196 funds tracked by Wall St. Rank hold ICPT as of Q2 2019.

Artal Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Artal Group sold 50,000 Intercept Pharmaceuticals, Inc. shares in Q2 2019, an estimated $5.59M.
Artal Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
Artal Group's Intercept Pharmaceuticals, Inc. position peaked at $5.59M in Q1 2019.
196 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2019.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.